Research Insights
Commentary and analysis on MASH endpoints, GLP-1 therapeutics, FDA regulatory developments, and the clinical science underlying complex pharmaceutical litigation.
Coming Soon
This section will feature regular commentary from Dr. Weston on developments in MASH drug development, cardiometabolic trial design, FDA guidance, and the scientific issues at the center of current pharmaceutical litigation. Articles are written for attorneys, institutional investors, and pharmaceutical executives — not general audiences.
How FDA guidance on histological and non-invasive surrogate endpoints has shifted the landscape for MASH drug development — and what it means for product liability exposure on approved and late-stage agents.
Coming Q3 2026
A clinical perspective on the emerging litigation landscape around GLP-1 receptor agonists — separating the trial evidence from the emerging legal theories and identifying where genuine scientific uncertainty exists.
Coming Q3 2026
Why the design of cardiovascular outcomes trials — specifically the composition and adjudication of MACE endpoints — creates defensibility questions that surface years later in product liability proceedings.
Coming Q4 2026
Stay Informed
Attorneys and pharmaceutical professionals may register to receive new articles as they are published. No marketing. No frequency commitments.
Your email is used only to deliver new articles. Unsubscribe at any time.